Newsroom | 95660 results
Sorted by: Latest
-
The Time to Talk about HIV is Now: ViiV Healthcare Launches "Still Here" PSA to Ignite Action Around HIV on National Youth HIV/AIDS Awareness Day
DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today released “Still Here,” a social media video campaign designed to spark crucial conversations about HIV among young people. This launch coincides with National Youth HIV/AIDS Awareness Day and aims to confront the alarming reality that HIV remains a significant and often overlooked public health issue, especially among young people. While great progress h...
-
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision...
-
Revvity to Hold Earnings Call on Tuesday, May 5, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the...
-
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced two-year median follow-up data from the Phase 2 RAMP 201 clinical trial that evaluated AVMAPKI® FAKZYNJA® combination therapy (avutometinib capsules; defactinib tablets) in patients with recurrent low-grade serous ovarian cancer (LGSOC) will be presented today during an oral plenary session at the Society o...
-
Bial Launches Education and Awareness Campaign for World Parkinson’s Day
PORTO, Portugal--(BUSINESS WIRE)--To mark World Parkinson’s Day, Bial today launches “Dialogues with Parkinson’s”....
-
Byondis宣布任命Christoph Korpus, PhD, MBA出任首席执行官
荷兰奈梅亨--(BUSINESS WIRE)--(美国商业资讯)-- 致力于为癌症患者开发创新靶向疗法的独立生物制药公司Byondis B.V.今日宣布，任命Christoph Korpus, PhD, MBA出任首席执行官（CEO），即刻生效。Christoph自2025年1月起担任公司首席商务官（CBO）。他将接任公司创始人、前首席执行官Jacques Lemmens, PhD。Jacques Lemmens将继续留任董事会，并出任董事会主席。 在出任首席执行官后，Christoph将负责引领Byondis新型抗体药物偶联物（ADC）技术平台的研发推进。该等平台将公司专有的创新载荷与先进的连接子及偶联技术相结合，并融入条件性激活机制，涵盖Byondis的细胞毒性抗叶酸连接子药物平台、用于实现条件性激活的ByonGuard™掩蔽技术，以及ByonBoost™免疫刺激型连接子药物平台。上述各技术平台均已产生处于领先地位的候选药物，并形成多项后续在研项目布局。依托一体化的药物发现、开发及生产能力，Byondis具备灵活开展研发的能力，可独立推进其核心候选产品的各项关键开发工作。在持续深化...
-
300 mil millones de dólares en ingresos de las ciencias biológicas están en riesgo. La inteligencia que los respalda tiene meses de atraso. Behavior Labs lanza una plataforma de decisiones inteligentes para salvar esta brecha.
AUSTIN, Texas--(BUSINESS WIRE)--Behavior Labs, una nueva empresa de inteligencia de ciencias biológicas, lanzó hoy una plataforma que ofrece inteligencia transparente continua para equipos de la industria farmacéutica y de dispositivos médicos, con asistencia de lo que la empresa denomina "World Model", un modelo de operación continua de la realidad del mercado donde existe cada producto. La plataforma reemplaza los ciclos de revisión trimestrales con un panorama diario de validación cruzada de...
-
300 miliardi di dollari a rischio nel settore delle scienze della vita. L’intelligence alla sua base è vecchia di mesi. Behaviour Labs lancia una piattaforma di intelligence decisionale che colma questa lacuna.
AUSTIN, Texas--(BUSINESS WIRE)--Behavior Labs, una nuova società specializzata in analisi di settore nel campo delle scienze della vita ha lanciato oggi una piattaforma che fornisce ai team del settore farmaceutico e dei dispositivi medici informazioni strategiche in tempo reale, basate su quello che l’azienda definisce un modello mondiale, ovvero un modello in continuo aggiornamento della realtà di mercato in cui ogni prodotto si inserisce. La piattaforma sostituisce i cicli di revisione trime...
-
300 Milliarden US-Dollar Umsatz in der Life-Sciences-Branche stehen auf dem Spiel. Die zugrunde liegenden Informationen sind Monate alt. Behavior Labs bringt eine Decision-Intelligence-Plattform auf den Markt, die diese Lücke schließt.
AUSTIN, Texas--(BUSINESS WIRE)--Behavior Labs, ein neues Unternehmen für Life-Sciences-Intelligence, hat heute eine Plattform eingeführt, die Teams aus den Bereichen Pharma und Medizinprodukte kontinuierlich strategische Informationen liefert – gestützt auf das sogenannte „World Model“, ein kontinuierlich arbeitendes Modell der Marktrealität, in der jedes Produkt existiert. Die Plattform ersetzt vierteljährliche Überprüfungszyklen durch tägliche, kreuzvalidierte Erkenntnisse über den gesamten P...
-
$ 300 miljard aan inkomsten uit Life Sciences in gevaar. De informatie erachter is maanden oud. Behavior Labs lanceert een beslissingsintelligentieplatform dat deze kloof aanpakt.
AUSTIN, Texas--(BUSINESS WIRE)--Behavior Labs, een nieuw bedrijf in Life Sciences-intelligentie, heeft vandaag een platform gelanceerd dat farmaceutische en medische apparatuurteams continue strategische informatie biedt – mogelijk gemaakt door wat het bedrijf een World Model noemt, een continu werkend model van de marktrealiteit waarin elk product bestaat. Het platform vervangt de driemaandelijkse beoordelingscycli door dagelijks, gevalideerd inzicht over de volledige levenscyclus van producte...
